Characteristic | Intervention(s) and comparator(s) | Deaths [N] | Deaths [%] | All adverse events [N] | All adverse events [%] | Severe/serious adverse events [N] | Severe/serious adverse events [%] |
Ludvik 2002 | I1: sweet potato (Caiapo) tablets 2 g | 0 | 0 | "No adverse events have been reported by the patients" | ‐ | ‐ | ‐ |
I2: sweet potato (Caiapo) tablets 4 g | 0 | 0 | |||||
C: placebo | 0 | 0 | |||||
Ludvik 2004 | I: sweet potato (Caiapo) tablets 4 g | 0 | 0 | 16/30 | 53.3 | ‐ | ‐ |
C: placebo | 0 | 0 | 14/31 | 45.2 | ‐ | ‐ | |
Ludvik 2008 | I: sweet potato (Caiapo) tablets 4 g | 0 | 0 | ‐ | ‐ | ‐ | ‐ |
C: placebo | 0 | 0 | ‐ | ‐ | ‐ | ‐ | |
Footnotes "‐" denotes not reported C: comparator; I: intervention |